Genscript Biotech Corporation
Genscript Biotech Corporation, a leading player in the biotechnology industry, is headquartered in China (CN) and operates extensively across North America, Europe, and Asia. Founded in 2002, Genscript has established itself as a pioneer in gene synthesis, peptide synthesis, and antibody development, catering to a diverse range of sectors including pharmaceuticals, diagnostics, and academic research. The company’s core offerings, such as its innovative gene editing tools and custom protein services, are distinguished by their high quality and rapid turnaround times. Genscript's commitment to advancing life sciences has earned it a prominent market position, with notable achievements including numerous collaborations with top-tier research institutions and a robust portfolio of intellectual property. As a trusted partner in biotechnological advancements, Genscript continues to drive innovation and support scientific discovery globally.
DitchCarbon Score
How does Genscript Biotech Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genscript Biotech Corporation's score of 58 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genscript Biotech Corporation's reported carbon emissions
In 2023, GenScript Biotech Corporation reported significant carbon emissions, totalling approximately 387,028,000 kg CO2e for Scope 1, 387,589,810 kg CO2e for Scope 2, and 114,034,820 kg CO2e for Scope 3. This data highlights the company's substantial carbon footprint across its operations. GenScript has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 54.6% by 2033, using 2023 as the baseline year. Additionally, it plans to cut Scope 3 emissions from fuel and energy-related activities and waste generated in operations by 32.5% within the same timeframe. For the long term, GenScript aims for a 90% reduction in both Scope 1 and 2 emissions by 2050, as well as a 90% reduction in Scope 3 emissions. Furthermore, the company is committed to ensuring that 83% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2029. These initiatives reflect GenScript's dedication to addressing climate change and reducing its environmental impact in the biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 387,028,000 | 00,000,000 |
| Scope 2 | 387,589,810 | 000,000,000 |
| Scope 3 | 114,034,820 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genscript Biotech Corporation is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
